tumor antigens

tu·mor an·ti·gens

1. antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific);
2. tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses.
Synonym(s): neoantigens (2)

See also: T antigens.

tu·mor an·ti·gens

(tū'mŏr an'ti-jenz)
1. Those antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific).
2. Tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses.
See also: T antigens
Synonym(s): neoantigens, tumour antigens.
References in periodicals archive ?
The tumor antigens must be presented to the body in a different form, or in a different way, to enlist the patient's own immune system in fighting the cancer.
Its novel, proprietary products are intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released.
While cancer vaccines create killer (CD8+) T cell immune responses against tumor antigens, oncolytic viruses leverage defective pathways in tumors to selectively replicate in and destroy cancer cells.
Receptors on the surface of T-cells recognize tumor antigens in the form of small peptides and provide a selective pathway for targeted cancer therapies.
Creation of a pure population of T cells, based on targeted screening for specific features, such as affinity to tumor antigens and anti-tumor activity, enables isolation of a single population of TCRs, which can then be sequenced.
The registered numbers of clinical trials increase annually, and a range of tumor antigens, including CEA, mesothelin, HER2, and GD2, are being targeted for various solid tumors.
Although their presentations vary, syndromes occur when tumor antigens exhibit cross-reactivity to similar antigens expressed by these systems.
According to this model, the expectation was that tumor antigens recognized by the lymphocytes infiltrating the tumors should be derived from oncogenic viruses or from somatically mutated genes generated during the processes of carcinogenesis.
Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
These nine articles describe some of the work being done to differentiate markers and use their presence to detect and treat a range of cancers, addressing the characterization of breast cancer subtypes in a large retrospective study, intraocular lymphoma markers, polymorphisms in genes associated with certain T-cell lymphomas, tumor antigens that are markers of minimal residual disease in acute myeloid leukemia, thyroid tumor markers, activity and expression of dipeptidyl peptidase IV and cathepsin H in human cutaneous melanoma compared to other common cancers, melanoma inhibitory activity as a serological marker in metastic melanoma, and the promise (or myth) of the tumor necrosis factor alpha receptors p55 and p75 in ovarian cancer detection.
The discovery of a central role for HMGB1 and TLR2 in overcoming immune ignorance to brain tumor antigens provides a new therapeutic approach in the fight against brain tumors.